# Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer

> **NCT00295802** · PHASE2,PHASE3 · UNKNOWN · sponsor: **EDAP TMS S.A.** · enrollment: 141 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DEVICE:** Integrated Imaging High Intensity Focused Ultrasound
- **DEVICE:** Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)

## Key facts

- **NCT ID:** NCT00295802
- **Lead sponsor:** EDAP TMS S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-04
- **Primary completion:** 2012-08
- **Final completion:** 2014-09
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2014-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295802, "Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00295802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*